In a report released today, Emily Field from Barclays maintained a Buy rating on Genmab A/S (0MGB – Research Report), with a price target ...

Janssen-Cilag International NV, a Johnson & Johnson (JNJ) company, announced Thursday the submission of a Type II variation ...

If you want a professional-looking logo for your business or blog but don’t have enough money to pay a graphic designer – or time to learn how to make it yourself – you’re in luck.

Daratumumab, hyaluronidase-fihj; 1800mg/30000units; per vial; soln for SC inj; preservative-free. Daratumumab binds to CD38 and inhibits the growth of CD38 expressing tumor cells by inducing ...

The previous Paralympic logo incorporated the Tae-Geuk, which is a traditional Korean decorative motif. According to oriental philosophy, Tae-Geuk refers to the ultimate reality from which all things ...

NICE has rejected Janssen’s Darzalex (daratumumab) for regular NHS funding in third line multiple myeloma, saying that gaps in clinical evidence mean cost-effectiveness data are unreliable.

Johnson & Johnson has claimed FDA approval for new formulation of its blockbuster multiple myeloma drug Darzalex that cuts its dosing time to just a few minutes from hours and could help it fend ...

In a Friday data drop from the phase 3 CEPHEUS study, J&J revealed that Darzalex Faspro combined with bortezomib, lenalidomide and dexamethasone (VRd) in first-line, transplant ineligible multiple ...

The best logo maker helps you craft the right branding for your business - even if you've never designed a logo before. Our team of expert reviewers have tested the best free logo makers and the ...

The company has a new logo, designed by Pentagram, that looks incredibly plain — especially compared to previous iterations of the logo that featured a rakish slant, two shades of blue ...

(RTTNews) - Johnson & Johnson (JNJ) Frday announced data from three studies highlighting clinical efficacy of Darzalex (daratumumab) and Darzalex Faspro (daratumumab and hyaluronidase-fihj ...

RIO DE JANEIRO - Johnson & Johnson (NYSE: JNJ) announced today that DARZALEX FASPRO®, when used in combination with lenalidomide as a maintenance therapy, has shown to significantly improve ...